摘要
目的探讨粪微生态移植联合柳氮磺吡啶对溃疡性结肠炎患者血清炎症因子及T细胞亚群的影响。方法选取我院于2018年6月~2019年12月期间收治的90例溃疡性结肠炎患者为研究对象,观察组给予粪微生态移植联合柳氮磺吡啶,对照组给予常规治疗,观察溃疡性结肠炎患者治疗前后血清炎症因子、Mayo评分、T细胞亚群及临床疗效。结果观察组有效率为95.5%,观察组有效率明显优于对照组,且Mayo评分较治疗前明显下降(P<0.05);观察组CRP、TNF-α、IL-6等炎症因子明显下降(P<0.05),且优于对照组(P<0.05);治疗后两组CD_(4)^(+)T细胞比例升高,CD_(4)^(+)/CD_(8)^(+)比值升高(P<0.05),观察组显著高于对照组(P<0.05)。结论粪微生态移植联合柳氮磺吡啶通过重建肠道正常菌群改善T细胞亚群,从而调节免疫状态,降低炎症反应,达到治疗溃疡性结肠炎的作用,且具有一定的安全性。
Objective To investigate the effects of fecal micro-ecological transplantation combined with sulfasalazine on serum inflammatory factors and T-cell subsets in patients with ulcerative colitis.Methods a study of 90 patients with UC admitted to our hospital from June 2018 to December 2019,the observation group was given fecal microecological transplantation combined with sulfasalazine,and the control group was given conventional treatment to observe serum inflammatory factors,Mayo score,T cell subsets and clinical efficacy before and after treatment in UC patients.Results The effective rate of the observation group was 95.5%.The effective rate of the observation group was significantly better than that of the control group,and the Mayo score was significantly lower than that before treatment(P<0.05).Inflammation of CRP,TNF-α,IL-6,etc.The factors were significantly decreased(P<0.05),and better than the control group(P<0.05).After treatment,the CD_(4)^(+)increased and the CD_(4)^(+)/CD_(8)^(+)ratio increased(P<0.05).The observation group was significantly higher than the control group(P<0.05).Conclusions FMT combined with sulfasalazine can improve the immune status of T cell subsets,reduce the inflammatory response,and achieve the effect of treating UC by establishing the normal intestinal flora.It has certain safety.
作者
孙莉莉
薛青
SUN Li-li;XUE Qing(Department of Health Care,Taigong Sanatorium,Wuxi,Jiangsu 21400)
出处
《临床输血与检验》
CAS
2021年第4期497-501,共5页
Journal of Clinical Transfusion and Laboratory Medicine
基金
无锡市卫生和计划生育委员会科研项目(No.CSEY1N1110)资助。
关键词
粪微生态移植
溃疡性结肠炎
炎症因子
T细胞亚群
Fecal microecological transplantation
Ulcerative colitis
Inflammatory factors
T cell subsets